2001 - 2014

 

I served as the CEO of Procognia, a biotech company traded on the TASE, where I established the company as a leader in biopharmaceutical analytics, established a cGMP facility, global strategic collaborations, marketing and sales unit, led the company from $3m annual loss to operational profitability.

 

Prior to that, I served as the CEO of Thrombotech, a multi-center phase II clinical development stage biotech company active in the fields of CNS and cardiovascular. I established company’s management and operation structure, raised $2 million, led business development activities and setting up of a multi-center clinical trial in Europe and Asia, and FDA and IND approval. Eventually, I led the company towards acquisition by an Israeli public pharmaceutical company. 

 

Prior to that, I served as the Chief Business Officer of YEDA Research and Development, the technology transfer company of the Weizmann Institute of Science, responsible for the commercialization of the WIS technologies. I led the business unit of Yeda, responsible for industrial commercialization of the WIS technologies. Responsibilities included IP and technology evaluation, marketing, licensing, and negotiation of commercial terms for over 120 technologies in the fields of pharmaceuticals, diagnostics, medical device, agriculture, energy, clean-tech, and nano-tech.

 

Prior to that, I served as a Vice President in several Biotech companies where she led diverse product development activities and clinical and pre-clinical R&D projects, Including Gamida Cell Ltd.,where I led a global phase II/III pivotal clinical trial project under Gamida Cell – Teva Joint Venture, for a cell-therapy-based treatment for hematological malignancies. Responsibilities involved integration of a multi-discipline team of over 100 people worldwide, coordinating clinical operations, regulatory affairs, manufacturing and QC, R&D, and commercial aspects.